Türkiyede Üçüncü Basamak bir Hastanede Son On Yılda Burkholderia Türlerinin Antibiyotik Dirençlerinin Değerlendirilmesi

Başbulut, Eşe; Bilgin, Melek; İşler, Hacer

doi:10.5578/flora.20229909

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total n=87 n (%) When comparing the resistance rates in five-year periods, they demonstrated that meropenem resistance decreased from 64.3% to 22.5% (p<0.001); levofloxacin resistance decreased from 50% to 4.9% in the last period (p<0.001). However, trimethoprim-sulfamethoxazole resistance rate increased from 9.5% to 14.6% in the last period (p>0.05) (19). In the study of El Chakhtoura et al, trimethoprim-sulfamethoxazole, fluoroquinolone, ceftazidime, and meropenem resistance rates were about 6%, 12%, 30%, and 30%, respectively (9).…”

Section: Parametersmentioning

confidence: 93%

Antimicrobial Susceptibility Profiles and Key Determinants for Mortality in Burkholderia cepacia Complex Infections

Özdemir,

Kaplan-Yazar,

Borcak

et al. 2023

Infect Dis Clin Microbiol

View full text Add to dashboard Cite

Objective: We aimed to define the clinical features and antimicrobial susceptibility profiles of Burkholderia cepacia complex infections and to determine the predictors for mortality. Materials and Methods: Our single-center retrospective study included patients with nosocomial B. cepacia complex infection between 2018 and 2022. We evaluated the predictors of 14-day and 28-day mortality by analyzing clinical and microbiological data. Results: A total of 87 patients were included. Most infections (79.3%) occurred in the intensive care units (ICUs). Among B. cepacia complex isolates, 74.7% were susceptible to trimethoprim-sulfamethoxazole, 70.3% to levofloxacin, 50% to meropenem, and 23.4% to ceftazidime. The rates of 14-day mortality, 28-day mortality, and in-hospital mortality were 41.3% (n=36), 52.8% (n=46), and 64.3% (n=56), respectively. Multivariate analysis revealed neutrophil/lymphocyte ratio (NLR) (odds ratio [OR]=1.05, p=0.024), platelet count (OR=1.00, p=0.011), creatinine (OR=2.14, p=0.006), and aspartate aminotransferase (AST) (OR=1.02, p=0.028) as predictors for 14-day mortality. In addition to NLR (OR=1.07, p=0.014), platelet count (OR=1.00, p=0.039), creatinine (OR=2.05, p=0.008), and AST (OR=1.02, p=0.035), procalcitonin (OR=1.05, p=0.049) was also found as an independent predictor for 28-day mortality. In receiver operating characteristic (ROC) curve analysis for predicting 14-day mortality, area under the ROC curve (AUC) values were 0.684 (p=0.003) in NLR, 0.719 (p<0.001) in platelet count, 0.673 (p=0.003) in procalcitonin, 0.743 (p<0.001) in creatinine, and 0.700 (p<0.001) in AST. In ROC curve analysis for predicting 28-day mortality, AUC values were 0.674 (p=0.002) in NLR, 0.651 (p=0.010) in platelet count, 0.638 (p=0.020) in procalcitonin, 0.730 (p<0.001) in creatinine, and 0.692 (p=0.001) in AST. Conclusion: Increasing antibiotic resistance and higher mortality rates justify that B. cepacia complex is a significant threat to hospitalized patients, especially in ICUs. Elevated levels of NLR, AST, creatinine, procalcitonin, and decreased platelet may predict poor clinical outcomes and could help clinicians in the management of this notorious bacterial pathogen. Keywords: antimicrobial susceptibility, antibiotic resistance, Burkholderia cepacia complex, mortality, predictors

show abstract

Section: Parametersmentioning

confidence: 93%